Contacting Audion, Patients
Thank you for your interest in Audion. We currently do not have an ongoing clinical study. Until then we will not be able to answer requests from patients to participate in a future clinical trial, or any trial related questions.
We do apologise for any inconvenience this may cause. Future clinical studies will be announced on the Audion website and published through other public channels.
Any personal information that is and was sent through the contact page will not be transferred to third parties, and will be kept securely by Audion with your consent only.
This website contains information relating to health, diseases and treatments. This is for information purposes only and is not meant to be a substitute for the advice provided by your own doctor or healthcare professional. You should not use the information contained herein for diagnosing any illness or physical or mental issue. Audion will not respond to any such request, you should always consult your own doctor or healthcare professional.
This contact form can also be used to contact us to request information about what personal data is stored by us and for what purpose it is stored. In addition, you may have incorrect data corrected or data deleted that is inadmissible or no longer necessary to be stored even if you have given us consent to do so. We are at your disposal for information, wishes or suggestions on the subject of data protection.
Contacting Audion, partners and collaborators
Our lead drug development program, LY3056480, is aimed at treating sensorineural hearing loss by regenerating lost inner ear hair cells. The goal of the drug development program is to obtain safety and clinical proof of concept data with a proprietary gamma-secretase inhibitor licensed from Eli-Lilly and identified by Eli Lilly and Audion scientists. The first clinical study for LY3056480 was funded among others by an EU Horizon2020 grant (REGAIN, http://www.regainyourhearing.eu). If you are interested in Audion’s LY3056480 program, investing, and M&A or partnering with Audion you are welcome to contact us through this page.